Published in Oncotarget on July 12, 2016
The discontinuity theory of immunity. Sci Immunol (2016) 0.75
Inflammation and cancer. Nature (2002) 53.78
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Biophysical and molecular mechanisms of Shaker potassium channel inactivation. Science (1990) 15.75
A study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol (1957) 15.07
Origin and physiological roles of inflammation. Nature (2008) 11.68
Plasmacytoid dendritic cells in immunity. Nat Immunol (2004) 9.11
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Trophic macrophages in development and disease. Nat Rev Immunol (2009) 5.37
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 5.22
Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci U S A (1995) 5.01
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
War and peace at mucosal surfaces. Nat Rev Immunol (2004) 4.00
Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity (2014) 3.94
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41
The incoherent feedforward loop can provide fold-change detection in gene regulation. Mol Cell (2009) 3.38
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science (1998) 3.15
Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol (2001) 3.08
Control of pathogens and pathobionts by the gut microbiota. Nat Immunol (2013) 2.84
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med (2015) 2.20
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Evolution of antigen binding receptors. Annu Rev Immunol (1999) 1.99
Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity (2005) 1.83
Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther (1994) 1.83
IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition. J Immunol (2004) 1.74
The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol (2013) 1.72
Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J (2003) 1.72
T cell adhesion primes antigen receptor-induced calcium responses through a transient rise in adenosine 3',5'-cyclic monophosphate. Immunity (2009) 1.59
Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One (2011) 1.55
The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med (2015) 1.44
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell (2014) 1.43
A new vision of immunity: homeostasis of the superorganism. Mucosal Immunol (2010) 1.38
CAR T cells for solid tumors: armed and ready to go? Cancer J (2014) 1.29
Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int (2013) 1.24
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
On the definition of a criterion of immunogenicity. Proc Natl Acad Sci U S A (2006) 1.06
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther (2015) 1.06
The price of immunity. Nat Immunol (2012) 1.04
T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks. Elife (2014) 1.02
GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med (2010) 1.00
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opin Biol Ther (2012) 0.95
Translational medicine in action: anti-CD20 therapy in lymphoma. J Immunol (2014) 0.93
Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res (2014) 0.88
Revisiting the role of T cells in tumor regression. Oncoimmunology (2012) 0.81
Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. Oncotarget (2015) 0.77